Esmolol - Revision history

Jhollowa: Added onset of action and metabolism details, specifically RBC esterase metabolism.

2023-05-31T17:07:54Z

Added onset of action and metabolism details, specifically RBC esterase metabolism.

← Older revision		Revision as of 10:07, 31 May 2023
Line 46:		Line 46:

	=== Pharmacokinetics<!-- Describe the pharmacokinetics of the drug. --> ===		=== Pharmacokinetics<!-- Describe the pharmacokinetics of the drug. --> ===

			==== Onset of action ====
			Beta-blockade with esmolol can be observed within 2-10 minutes of administration. Onset is typically quicker when administered as a bolus or with a loading dose prior to infusion.<ref name=":1" />

			==== Metabolism ====
			Esmolol is metabolized by red blood cell esterases to inactive metabolites, which are renally excreted. <ref name=":1" />

	== Chemistry and formulation<!-- Describe the chemistry and formulation of the drug. --> ==		== Chemistry and formulation<!-- Describe the chemistry and formulation of the drug. --> ==

Chris.Rishel at 21:26, 22 December 2022

2022-12-22T21:26:49Z

← Older revision		Revision as of 14:26, 22 December 2022
Line 7:		Line 7:
	\| contraindications =		\| contraindications =
	\| routes = Intravenous		\| routes = Intravenous
	\| dosage = ~~Attenuating cardiovascular response to laryngoscopy:~~		\| dosage =
	~~Adult: 0.2-0.5 mg/kg IV bolus~~

	~~Perioperative tachycardia and hypertension:~~
	~~Adult: 0.5-1 mg/kg IV bolus. Can start an infusion at 50 mcg/kg/minute and titrate up to a maximum rate of 300 mcg/kg/minute.~~
	\| dosage_calculation = esmolol		\| dosage_calculation = esmolol
	\| mechanism = Beta-1 antagonism		\| mechanism = Beta-1 antagonism

Sydneyjaj: Added information about esmolol

2022-12-21T20:10:11Z

Added information about esmolol

← Older revision		Revision as of 13:10, 21 December 2022
Line 7:		Line 7:
	\| contraindications =		\| contraindications =
	\| routes = Intravenous		\| routes = Intravenous
	\| dosage =		\| dosage = Attenuating cardiovascular response to laryngoscopy:
			Adult: 0.2-0.5 mg/kg IV bolus

			Perioperative tachycardia and hypertension:
			Adult: 0.5-1 mg/kg IV bolus. Can start an infusion at 50 mcg/kg/minute and titrate up to a maximum rate of 300 mcg/kg/minute.
	\| dosage_calculation = esmolol		\| dosage_calculation = esmolol
	\| mechanism = Beta-1 antagonism		\| mechanism = Beta-1 antagonism
	\| adverse_effects =		\| adverse_effects = Bradycardia, Hypotension
	\| time_onset =		\| time_onset =
	\| duration =		\| duration =
Line 20:		Line 24:
	}}		}}

	~~Provide a brief summary~~ of ~~this drug here~~.		Esmolol is an ultrashort-acting selective β1-antagonist. It primarily decreases heart rate with less of an effect on blood pressure. <ref name=":0">{{Cite book\|url=https://www.worldcat.org/oclc/1309921315\|title=Morgan & Mikhail's clinical anesthesiology\|date=2022\|others=John F., IV Butterworth, David C. Mackey, John D. Wasnick\|isbn=9781260473797\|edition=Seventh edition\|location=New York\|oclc=1309921315}}</ref>

	== Uses<!-- Describe uses of the drug. If appropriate, add subsections for each indication. --> ==		== Uses<!-- Describe uses of the drug. If appropriate, add subsections for each indication. --> ==
			Treat/prevent perioperative tachycardia and hypertension .

			Opioid sparing anesthesia.<ref name=":0" />

	== Contraindications<!-- List contraindications and precautions for use of the drug. --> ==		== Contraindications<!-- List contraindications and precautions for use of the drug. --> ==
Line 29:		Line 36:

	=== Precautions<!-- List precautions for use of the drug. If none, this section may be removed. --> ===		=== Precautions<!-- List precautions for use of the drug. If none, this section may be removed. --> ===
			While it is cardioselective at lower doses, use higher doses cautiously in patients with bronchospastic disease. <ref name=":1">{{Cite web\|title=UpToDate - Esmolol: Drug information\|url=https://www.uptodate.com/contents/esmolol-drug-information?source=auto_suggest&selectedTitle=1~1---1~4---esmolol&search=esmolol#F166853\|url-status=live\|access-date=2022-12-21\|website=www.uptodate.com}}</ref>

			Extreme caution should be used in patients with bradycardia, hypotension, greater than first degree heart block, cardiogenic shock or heart failure with reduced ejection fraction.<ref name=":0" /> Avoid in patients who recently received a calcium channel blocker. <ref name=":1" />

	== Pharmacology ==		== Pharmacology ==
Line 35:		Line 45:

	==== Mechanism of action<!-- Describe the mechanism of action for the primary uses of the drug. --> ====		==== Mechanism of action<!-- Describe the mechanism of action for the primary uses of the drug. --> ====
			At normal doses it is a selective β1-antagonist, at higher doses it also inhibits β2 receptors in both bronchial and vascular smooth muscle. <ref name=":0" />

	==== Adverse effects<!-- Describe any potential adverse effects of the drug. --> ====		==== Adverse effects<!-- Describe any potential adverse effects of the drug. --> ====

Chris.Rishel: Added embedded dosage calculation

2022-03-30T07:57:54Z

Added embedded dosage calculation

← Older revision		Revision as of 00:57, 30 March 2022
Line 8:		Line 8:
	\| routes = Intravenous		\| routes = Intravenous
	\| dosage =		\| dosage =
			\| dosage_calculation = esmolol
	\| mechanism = Beta-1 antagonism		\| mechanism = Beta-1 antagonism
	\| adverse_effects =		\| adverse_effects =

Chris.Rishel at 23:26, 12 November 2021

2021-11-12T23:26:02Z

← Older revision		Revision as of 16:26, 12 November 2021
Line 49:		Line 49:
	[[Category:Beta blockers]]		[[Category:Beta blockers]]
	[[Category:Beta-1 antagonists]]		[[Category:Beta-1 antagonists]]
			[[Category:Chronotropes]]
			[[Category:Negative chronotropes]]

Chris.Rishel at 23:23, 12 November 2021

2021-11-12T23:23:18Z

← Older revision		Revision as of 16:23, 12 November 2021
Line 48:		Line 48:
	[[Category:Adrenergic receptor modulators]]		[[Category:Adrenergic receptor modulators]]
	[[Category:Beta blockers]]		[[Category:Beta blockers]]
	[[Category:Beta-1 ~~selective~~ antagonists]]		[[Category:Beta-1 antagonists]]

Chris.Rishel at 23:03, 12 November 2021

2021-11-12T23:03:44Z

← Older revision		Revision as of 16:03, 12 November 2021
Line 1:		Line 1:
	{{Infobox drug reference		{{Infobox drug reference
	\| trade_names =		\| trade_names = Brevibloc
	\| drug_class =		\| image_file = Esmolol.svg
	\| drug_class_color =		\| drug_class = Beta blocker
			\| drug_class_color = cardiovascular_antagonist
	\| uses =		\| uses =
	\| contraindications =		\| contraindications =
	\| routes =		\| routes = Intravenous
	\| dosage =		\| dosage =
			\| mechanism = Beta-1 antagonism
			\| adverse_effects =
			\| time_onset =
			\| duration =
			\| metabolism =
			\| halflife_redistribution =
			\| halflife_elimination =
			\| clearance =
			\| protein_binding =
	}}		}}

Line 36:		Line 46:

	[[Category:Drug reference]]		[[Category:Drug reference]]
			[[Category:Adrenergic receptor modulators]]
			[[Category:Beta blockers]]
			[[Category:Beta-1 selective antagonists]]

Oliviamsutton: Created page with "{{Infobox drug reference | trade_names = | drug_class = | drug_class_color = | uses = | contraindications = | routes = | dosage = }} Provide a brief summary of this dr..."

2021-11-10T17:26:23Z

Created page with "{{Infobox drug reference | trade_names = | drug_class = | drug_class_color = | uses = | contraindications = | routes = | dosage = }} Provide a brief summary of this dr..."

New page

{{Infobox drug reference
| trade_names =
| drug_class =
| drug_class_color =
| uses =
| contraindications =
| routes =
| dosage =
}}

Provide a brief summary of this drug here.

== Uses ==

== Contraindications ==

=== Absolute contraindications ===

=== Precautions ===

== Pharmacology ==

=== Pharmacodynamics ===

==== Mechanism of action ====

==== Adverse effects ====

=== Pharmacokinetics ===

== Chemistry and formulation ==

== History ==

== References ==

[[Category:Drug reference]]